News

Pursuant to the terms of the license agreement, Nile will pay development milestones and royalties based on sales of the licensed product. CU-NP was designed by researchers at

The new approvals bring the total number of China Sky One’s externally used products to 53 and its total marketed products to 102, giving the company one of

The initial study will evaluate the safety, tolerability, and the potential of INO-8875 to lower intraocular pressure (IOP) in glaucoma patients. Glaucoma patients typically have elevated levels of

Impulse Monitoring (IMI) will provide Emory-Adventist with comprehensive intraoperative neuromonitoring (IONM) services including IMI-qualified neurophysiologists and real-time professional oversight by an experienced physician. IONM assesses neurological function involving

Under the agreement, Bionomics will receive an upfront payment of $2 million and committed research funding. Merck Serono will fund all development activities, including clinical development. Merck Serono

Prior to joining Danube, Dr Katz served as executive vice president and chief medical officer of Fovea Pharmaceuticals in Paris. Before that Dr Katz was vice president for

The new development programs include response prediction to ovarian cancer treatment, predicting risk of gastric cancer recurrence, and differentiation of small cell from non-small cell lung cancer. The

Mr Tulstrup takes over as CEO from Keith McCullagh, who is retiring but will remain a member of the board of directors of the company. Prior to joining

The agreement marks the first immunotherapy clinical trial funded by Leukemia & Lymphoma Society’s (LLS) Therapy Acceleration Program, an innovative program designed to advance therapies with high prospects